2023
DOI: 10.1016/j.ijpharm.2023.122948
|View full text |Cite
|
Sign up to set email alerts
|

Reverse engineering of Perseris and development of compositionally equivalent formulations

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2025
2025

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(1 citation statement)
references
References 22 publications
0
1
0
Order By: Relevance
“…Introducing more LAI formulations requires a better understanding of the mechanisms of drug loading and release from LAI formulations. Recent studies on PLGA formulations initiated by the FDA have produced a wealth of information on the nature of PLGA polymers, the impact of PLGA polymer types on the drug releaser properties, the impact of processing parameters on the drug release kinetics, and reverse engineering. …”
Section: Future Ddssmentioning
confidence: 99%
“…Introducing more LAI formulations requires a better understanding of the mechanisms of drug loading and release from LAI formulations. Recent studies on PLGA formulations initiated by the FDA have produced a wealth of information on the nature of PLGA polymers, the impact of PLGA polymer types on the drug releaser properties, the impact of processing parameters on the drug release kinetics, and reverse engineering. …”
Section: Future Ddssmentioning
confidence: 99%